THC & Politics
March 15, 2026
Massachusetts' cannabis industry is drowning in debt, and policymakers are wrestling with a fundamental question: should government intervene in a market that's being crushed by the very rules designed to regulate it? The state's pot shops, cultivators, and associated companies can't pay their lenders, taxes, or suppliers—a crisis that highlights the broader struggle facing legal cannabis. An oversaturation of marijuana plants has cratered prices in an industry where entrepreneurs lack access to traditional financial tools like bank loans. The numbers tell the story: 113 million plants were harvested in December 2025 compared to around 10 million in late 2020, sending the average retail price for an ounce of flower plummeting from more than $400 in 2020 to $114.82 this January. 💰 MONEY MOVES Massachusetts' cannabis industry generated $289 million in taxes last year and employs 21,000 people—making it a significant part of the state's economy, yet one that's structurally disadvantaged compared to every other legal business.
The industry's distress stems from rules treating cannabis differently from other sectors. Stores and growers pay "impact" fees to localities that other businesses don't. They face higher federal taxes because the federal government still classifies cannabis as illegal. They can't access traditional bank loans, relying instead on private lenders offering less-favorable terms. Municipal zoning restrictions drive rents through the ceiling. Strict regulations governing security and product tracking make operating expensive. It's a policy paradox: legalization without the financial infrastructure or equal treatment that would allow the market to function. The question now facing Massachusetts regulators and lawmakers is whether a free market—one already distorted by federal prohibition and state-level restrictions—can rightsize itself, or whether targeted government intervention is necessary to prevent an entire legal industry from collapsing under the weight of the very regulations meant to control it.
Meanwhile, across the country in Missouri, lawmakers are taking a different approach to cannabis governance. 💰 MONEY MOVES Missouri's microbusiness program—designed as a social-equity initiative to boost cannabis opportunities for people in disadvantaged communities most impacted by the war on drugs—has become a cautionary tale about predatory contracts and regulatory capture. Of the 105 microbusiness licenses issued since the program launched in 2023, 35 have been revoked. Missouri's Division of Cannabis Regulation documented a pattern where well-connected groups and individuals flood the lottery by recruiting eligible applicants, then offer them contracts that strip away profit and control. Amy Moore, director of the division, told lawmakers this week: "There's really no question in many cases. Third parties used eligible individuals, names and circumstances to attempt to acquire licenses for themselves." A state panel approved new rules Thursday to tighten oversight by moving regulators' ownership review to before licenses are issued rather than after—a shift aimed at preventing another wave of revocations. However, lawmakers rejected a proposed ban on people tied to denied or revoked licenses from holding interests in future microbusinesses, with Republican state Rep. Ben Keathley arguing the language was too broad. The result is a partial fix that addresses one problem while leaving a door open for repeat players.
In eight states, a different kind of cannabis regulation is emerging—one aimed at allowing healthcare providers to refuse cannabis treatment on religious or moral grounds. Legislation in Kentucky, Missouri, New Hampshire, Oklahoma, Rhode Island, South Carolina, Utah, and West Virginia would expand medical conscience laws originally designed to protect providers from participating in abortion. These new bills would let doctors, nurses, hospitals, and even insurance companies refuse to provide or pay for care ranging from contraception and fertility services to medical marijuana and childhood vaccines. Supporters, including the Sutherland Institute, argue such measures protect providers from being sued or demoted for following deeply held beliefs. But critics warn the measures are dangerously broad—allowing providers to deny just about anything and undermining patients' expectations of comprehensive, informed care. The Tennessee case crystallized the debate: a woman scheduled for sterilization was already prepped with an IV when hospital staff cancelled the procedure, citing a "duty to protect her sacred fertility." At least five states have already passed expanded medical conscience laws. 🤔 THINK ABOUT IT These bills are advancing in the name of religious freedom while targeting a substance with zero recorded overdose deaths in human history—yet alcohol, which kills approximately 95,000 Americans annually, remains universally accessible through healthcare systems and legal commerce.
The political landscape is shifting alongside these regulatory battles. Virginia's 2026 legislative session wrapped up Saturday with lawmakers making decisions that will shape the state's cannabis future, though specifics from the session remain sparse in available reporting. And in Nebraska, an independent mechanic named Dan Osborn is challenging billionaire scion Pete Ricketts for a U.S. Senate seat, framing his campaign around what he calls "paycheck populism"—a direct-versus-establishment narrative that could reshape how cannabis policy is debated at the federal level. These political shifts matter because they reflect broader tensions: should cannabis policy be shaped by incumbents with deep ties to pharmaceutical, alcohol, and tobacco interests, or by lawmakers more representative of working communities where cannabis normalization has already won public support? The Massachusetts debt crisis, Missouri's equity program struggles, and the push for religious refusal laws all point to the same underlying problem—cannabis remains trapped between state legalization and federal prohibition, regulated unevenly, funded inequitably, and sometimes blocked entirely by politicians using moral frameworks that don't apply to demonstrably more dangerous substances. 🚀 THIS IS COOL What's genuinely encouraging is that states are experimenting with solutions: moving oversight timelines, expanding access protections, and wrestling publicly with how to build a legal industry that actually works. The question is whether those experiments can outpace the regulatory capture and political obstruction that's defined cannabis policy for the past 50 years.
Sources
